Kolexia
Martin Laurent Pharmacien
Martin Laurent
Pharmacien
Orphelia Pharma
Paris, France
12 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hypersensibilité Hypersensibilité aux arachides Hypersensibilité alimentaire Hypersensibilité immédiate Hypersensibilité au lait {{person.topmesh7.name}} {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Benhamou Pierre-Henri
Benhamou Pierre-Henri
Dbv Technologies, Montrouge, France
Dupont Christophe
Dupont Christophe
Hôpital Necker Enfants Malades, Paris, France
Delebarre-Sauvage Christine
Delebarre-Sauvage Christine
Hôpital Saint Vincent de Paul Lille, Lille, France
Bourrier Thierry
Bourrier Thierry
Fondation Lenval - Hôpital pour enfants, Nice, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients.
Pharmaceuticals (Basel, Switzerland)   29 avril 2022
Epicutaneous immunotherapy for peanut allergy modifies IgG responses to major peanut allergens.
The Journal of allergy and clinical immunology   31 octobre 2018
Increasing Clinical Peanut Thresholds Through Immunotherapy: Quantitative Assessment of the Safety Benefits Associated with Achieving a 300 or 1000 mg Peanut Protein Threshold.
Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2017 AAAAI Annual Meeting.   01 février 2017
Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch.
The Journal of allergy and clinical immunology   24 février 2016
Enhanced Efficacy and Confirmed Safety of a Two-Year Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® Peanut: The Continuation of the Vipes Phase IIb Randomized Controlled Trial (RCT)
Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2016 AAAAI Annual Meeting. All abstracts are strictly embargoed until the date of presentation at the 2016 Annual Meeting. Contact media@aaaai.org with questions.   01 février 2016
Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds through Immunotherapy
Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2016 AAAAI Annual Meeting. All abstracts are strictly embargoed until the date of presentation at the 2016 Annual Meeting. Contact media@aaaai.org with questions.   01 février 2016
Safety of Viaskin Milk Epicutaneous Immunotherapy (EPIT) in IgE-Mediated Cow's Milk Allergy (CMA) in Children (MILES Study)
Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2016 AAAAI Annual Meeting. All abstracts are strictly embargoed until the date of presentation at the 2016 Annual Meeting. Contact media@aaaai.org with questions.   01 février 2016
Epicutaneous Immunotherapy (EPIT) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial
Program and Abstracts of Papers to be Presented During Scientific Sessions: 2015 AAAAI Annual Meeting. All abstracts are strictly embargoed until the date of presentation at the 2015 Annual Meeting   01 février 2015
Epicutaneous Immunotherapy (EPIT) Is Safe for the Treatment of Peanut Allergy in Allergic Patients
Program and Abstracts of Papers to be Presented During Scientific Sessions: 2013 AAAAI Annual Meeting. All abstracts are strictly embargoed until the date of presentation at the 2013 Annual Meeting   01 février 2013
Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy: Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects
Essai Clinique (DBV Technologies)   22 mars 2012